REFERENCES
- Mishell DRjr, Talas M, Parlow AF, Moyer DL. Contraception by means of a Silastic vaginal ring impregnated with medroxy progesterone acetate. Am J Obstet Gynecol 1970;107:100–7.
- Sarkar NN. Development of contraceptive vaginal ring for fertility regulation of women. Int Med J 2003; 10: 119–126.
- Sarkar NN. Steroidal contraceptive vaginal ring. Int J Clin Pract 2003;57:392–5.
- Roumen FJ, Dieben TO. Clinical acceptability of an ethylene-vinyl-acetate non-medicated vaginal ring. Contraception 1999;59:59–62.
- de Leede LGJ, Govers CPM, de Nijs S. A multi- compartment vaginal ring system for independently adjustable release of contraceptive steroids. Contraception 1986;34:589–602.
- Roumen FJ, Dieben TO, Assendorp R, Bouckaert P. The clinical acceptability of a non-medicated vaginal ring. Contraception 1990;42:201–7.
- Olsson S-E, Odlind V. Contraception with a vaginal ring releasing 3-keto desogestrel and ethinyloestradiol. Con- traception 1990;42:563–72.
- Timmer CJ, Srivastava N, Dieben TO, Cohen AF. Bioavailability and bioequivalence of etonorgestrel from two oral formulations of desogestrel: Cerazette and Liseta. Eur J Drug Metab Pharmacokinet 1999;24:335–43.
- Timmer CJ, Mulders TM. Pharmacokinetics of etonorgestrel and ethinyloestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000; 39:233–42.
- Bergink EW, Hamburger AD, de Japer E, van der Vies J. Binding of a contraceptive progestogen org-2969 and its metabolites to receptor proteins and human sex hormone binding globulin. J Steroid Biochem 1981;14:175–83.
- Timmer CJ, Apter D, Voortman G. Pharmacokinetics of 3-keto-desogestrel and ethinyloestradiol released from different types of contraceptive vaginal rings. Contra- ception 1990;42:629–42.
- Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring, for ovulation inhibition. Fertil Steril 2001;75:865–70.
- Mulders TM, Dieben TO, Bennink HJ. Ovarian function with a novel combined contraceptive vaginal ring. Hum Reprod 2002;17:2594–9.
- Killick S. Complete and robust ovulation inhibition with NuvaRing. Eur J Contracept Reprod Health Care 2002; 7 (Suppl 2): 13–18.
- Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonorgestrel and ethinyloestradiol. Hum Reprod 2001; 16: 469–75.
- Roumen FJ. Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing. Eur J Contracept Reprod Health Care 2002; 7 (Suppl 2):19–24.
- Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002; 100: 585–93.
- Verhoeven CH, Dieben TO. The combined contra- ceptive vaginal ring, NuvaRing, and tampon co-usage. Contraception 2004;69:197–9.
- Haring T, Mulders TM. The combined contraceptive ring NuvaRing and spermicide co-medication. Contraception 2003;67:271–2.
- Szarewski A. High acceptability and satisfaction with NuvaRing use. Eur J Contacept Reprod Health Care 2002; 7 (Suppl 2): 31–6.
- Novak A, de la Loge C, Abetz L, van der Meulen EA. The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception 2003;67:187–94.
- Novak A, de la Loge C, Abetz L. Development and validation of an acceptability and satisfaction questionnaire for a contraceptive vaginal ring, NuvaRing. Pharmacoeconomics 2004;22:245–56.
- Bjarnadottir RT, Tuppurainen M, Killick SR. Compar- ison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyloestradiol. Am J Obstet Gynecol 2002;186:389–95.
- Vree M. Lower hormone dosage with improved cycle control. Eur J Contracept Reprod Health Care 2002; 7 (Suppl 2): 25–30.
- Roumen FJ, Boon ME, van Velzen D, Dieben TO, Coelingh-Bennink HJ. The cervicovaginal epithelium during 20 cycles use of a combined contraceptive vaginal ring. Hum Reprod 1996;11:2443–8.